Buprenorphine and Naloxone · BUPRENORPHINE 2 mg/1; NALOXONE .5 mg/1 · Tablet · Sublingual · Lannett Company, Inc.
NDC 62175-0452-32 · 30 TABLET in 1 BOTTLE · ANDA · View full market →
14 companies supply this market — deep enough that no single failure threatens the supply. The price is down 15% over the past year, to $0.4620 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Bryant Ranch Prepack | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Actavis Pharma, Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| American Health Packaging | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| American Health Packaging | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals LLC | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals LLC | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvPAK | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvPAK | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | BUPRENORPHINE 8 mg/1; NALOXONE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | BUPRENORPHINE 2 mg/1; NALOXONE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Aug 5, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Aug 5, 2026 | Sep 2, 2026 |
| Lannett Company, Inc. | BUPRENORPHINE 8 mg/1; NALOXONE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lannett Company, Inc. | BUPRENORPHINE 2 mg/1; NALOXONE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Redpharm Drug | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Remedyrepack Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rhodes Pharmaceuticals LLC | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rhodes Pharmaceuticals LLC | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Unit Dose Solutions, Inc. | BUPRENORPHINE HYDROCHLORIDE 8 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE .5 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Buprenorphine and Naloxone — NDC 62175-0452-32," retrieved September 3, 2026, https://drugdashboards.com/drug/62175045232.
Free to cite with attribution — see how the data is put together.